CING
Cingulate Inc
NASDAQ: CING · HEALTHCARE · BIOTECHNOLOGY
$4.71
+0.64% today
Updated 2026-04-29
Market cap
$67.01M
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-4.44
Dividend yield
—
52W range
$3 – $12
Volume
0.5M
WallStSmart proprietary scores
16
out of 100
Grade: F
Strong Sell
Investment rating
4.3
Growth
C5.0
Quality
C+3.0
Profitability
D5.0
Valuation
C+—/9
Piotroski F-Score
—
—
Altman Z-Score
—
—
Industry rank
—
View all highly rated stocks (75+) →200 stocks currently score above 75
Price targets
Analyst target
$28.70
+509.34%
12-Month target
—
—
Intrinsic (DCF)
—
Margin of safety
—
1 Strong Buy2 Buy0 Hold0 Sell0 Strong Sell
Price chart
X-Ray snapshot
Strengths
Insufficient data
Risks
- Thin margins at 0.00%
- Negative free cash flow $-9.52M
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net income | $-17.85M | $-23.53M | $-15.55M | $-22.45M | $-6.52M |
| EPS | — | — | — | — | $-4.44 |
| Free cash flow | $-16.04M | $-15.26M | $-18.66M | $-17.41M | $-9.52M |
| Profit margin | — | — | — | — | — |
Peer comparison
Smart narrative
Cingulate Inc trades at $4.71. Our Smart Value Score of 16/100 indicates the stock is weak.
Frequently asked questions
What is Cingulate Inc's stock price?
Cingulate Inc (CING) trades at $4.71.
Is Cingulate Inc overvalued?
Smart Value Score 16/100 (Grade F, Strong Sell).
What is the price target of Cingulate Inc (CING)?
The analyst target price is $28.70, representing +509.3% upside from the current price of $4.71.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio—
ROE-450.60%
Beta-0.77
50D MA$6.58
200D MA$4.92
Shares out0.01B
Float0.01B
Short ratio—
Avg volume0.5M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—